The FDA has approved Myqorzo for the treatment of adults with symptomatic oHCM to improve functional capacity and symptoms.
Giredestrant shows significant improvement in iDFS in patients with early-stage, HR-positive, HER2-negative breast cancer.
Recommendations have been presented for infection prevention and control (IPC) in the context of nursing homes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback